Most Read Articles
11 Oct 2019
Blood transfusion occurs with a striking frequency among autologous breast reconstruction patients and is associated with an increased risk of surgery-related complications, a recent study has found.
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
09 Nov 2019
In patients with acute ST-segment elevation myocardial infarction (ASTEMI), the risk of new-onset atrial fibrillation (NOAF) appears to be linked with plasma levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC), a recent China study has found.
Pank Jit Sin, 16 Oct 2019
While a diagnosis of cancer is often met with concern and devastation, the same is barely true for heart failure. However, the mortality rate for those suffering from heart failure is worse than some common cancers, such as prostate and breast cancers. 

Ticagrelor boosts aspirin in patients with diabetes, prior PCI, stable CAD

30 Sep 2019

The addition of ticagrelor to aspirin leads to better outcomes in patients with diabetes, previous percutaneous coronary intervention (PCI) and stable coronary artery disease (CAD), a recent study has found. The combination may also increase the risk of major bleeding, however.

Researchers randomly assigned 11,154 patients with previous PCI to receive either ticagrelor or placebo. The primary efficacy outcome was the composite of cardiovascular death, stroke or myocardial infarction.

Over a median follow-up of 3.3 years, 404 episodes (7.3 percent) of the primary outcome were reported in the ticagrelor group. This was significantly lower than that in the placebo group, in which 480 such episodes (8.6 percent) were documented (hazard ratio [HR], 0.85, 95 percent CI, 0.74–0.97; p=0.013).

In a separate analysis involving patients with no prior PCI, add-on ticagrelor did not yield such a benefit (8.2 percent vs 8.4 percent; HR, 0.98. 0.84–1.14; p=0.76).

The occurrence of ST-elevation myocardial infarction was also significantly suppressed in those who received ticagrelor (0.3 percent vs 0.9 percent; HR, 0.32, 0.18–0.55; p<0.0001). The same was true for another composite endpoint consisting of coronary, cerebral and peripheral ischaemic events.

On the other hand, major bleeding, according to the Thrombolysis in Myocardial Infarction (TIMI; HR, 2.03, 1.48–2.76; p<0.0001) and Platelet Inhibition and Patient Outcomes (PLATO; HR, 2.22, 1.72–2.86; p<0.0001) criteria, was significantly increased in those who were given ticagrelor.

This effect remained true even in those without a history of PCI (TIMI: HR, 2.79, 1.91–4.06; p<0.0001; PLATO: HR, 2.72, 1.99–3.72; p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Oct 2019
Blood transfusion occurs with a striking frequency among autologous breast reconstruction patients and is associated with an increased risk of surgery-related complications, a recent study has found.
05 Nov 2019
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
09 Nov 2019
In patients with acute ST-segment elevation myocardial infarction (ASTEMI), the risk of new-onset atrial fibrillation (NOAF) appears to be linked with plasma levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC), a recent China study has found.
Pank Jit Sin, 16 Oct 2019
While a diagnosis of cancer is often met with concern and devastation, the same is barely true for heart failure. However, the mortality rate for those suffering from heart failure is worse than some common cancers, such as prostate and breast cancers.